The Effectiveness of Mixed Reality as Interventional Tool for the Improvement on Quality of Life for People With Parkinson´s Disease. Randomized Control Trial

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Parkinson's disease is a chronic, neurodegenerative disease of unknown cause, affecting elderly people over the age of 60. It is the second most common neurodegenerative disease, presenting psychomotor signs and symptoms that lead to impaired functionality and quality of life in affected individuals. Mixed reality involves the delivery of digital stimuli in real time and space through spatial mapping using glasses, safely providing multiple iterations to carry out daily activities. Through this tool and in collaboration with technologically skilled mixed reality developers, the software for the rehabilitation program to be applied to Parkinson's disease patients was also developed. The main objective of this clinical study is to examine the effect of a mixed reality program compared to a traditional physiotherapy program on quality of life and motivation for the participation of people with Parkinson's disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Maximum Age: 100
Healthy Volunteers: t
View:

⁃ 1\. Male and female over 18 years old 2. Persons with independent gait 3. Normal cognitive ability 5. Greek Native language

• Male and female over 60 years old

• Persons with independent gait

• Normal cognitive ability

⁃ 5\. Greek Native language

Locations
Other Locations
Cyprus
University of Nicosia
RECRUITING
Nicosia
Contact Information
Primary
Elena Papamichael, PhD Cand
papamichael.e1@live.unic.ac.cy
99886346
Time Frame
Start Date: 2023-08-20
Estimated Completion Date: 2025-12-20
Participants
Target number of participants: 15
Treatments
Experimental: Mixed Reality interventional Group
Experimental: Traditional Physiotherapy Group
Placebo_comparator: Placebo group
Related Therapeutic Areas
Sponsors
Leads: University of Nicosia

This content was sourced from clinicaltrials.gov